Citius Pharmaceuticals
Citius Pharmaceuticals
CTXR
NASDAQ
3.78
USD
1.89%
About
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap.
LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Halo-Lido is a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids.
Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. NoveCite is a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.1M |
| Three Month Average Volume | 46.3M |
| High Low | |
| Fifty-Two Week High | 1.07 USD |
| Fifty-Two Week Low | 0.48 USD |
| Fifty-Two Week High Date | 02 Apr 2024 |
| Fifty-Two Week Low Date | 03 Jul 2024 |
| Price and Volume | |
| Current Price | 0.57 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -40.48% |
| Thirteen Week Relative Price Change | -23.65% |
| Twenty-Six Week Relative Price Change | -33.32% |
| Fifty-Two Week Relative Price Change | -50.13% |
| Year-to-Date Relative Price Change | -36.37% |
| Price Change | |
| One Day Price Change | 0.60% |
| Thirteen Week Price Change | -18.28% |
| Twenty-Six Week Price Change | -26.68% |
| Five Day Price Change | -4.20% |
| Fifty-Two Week Price Change | -37.51% |
| Year-to-Date Price Change | -24.65% |
| Month-to-Date Price Change | -37.02% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.57178 USD |
| Book Value Per Share (Most Recent Quarter) | 0.47411 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.13902 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.09372 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.2524 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.22271 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.24426 USD |
| Normalized (Last Fiscal Year) | -0.23811 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.22271 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.24426 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.22271 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.24426 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.1667 USD |
| Cash Per Share (Most Recent Quarter) | 0.09911 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.21508 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.23534 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.17878 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -19.77% |
| Tangible Book Value (5 Year) | 26.27% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -13.66% |
| EPS Change (Trailing Twelve Months) | -18.36% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 5 |
| Price to Tangible Book (Most Recent Quarter) | 6 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -17,911,190 |
| Net Debt (Last Fiscal Year) | -26,480,930 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 6 |
| Current Ratio (Most Recent Quarter) | 7 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -29,060,210 |
| Free Cash Flow (Trailing Twelve Months) | -29,088,900 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -29.91% |
| Return on Assets (Trailing Twelve Months) | -36.91% |
| Return on Assets (5 Year) | -30.26% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -34.80% |
| Return on Equity (Trailing Twelve Months) | -43.37% |
| Return on Equity (5 Year) | -35.18% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -31.58% |
| Return on Investment (Trailing Twelve Months) | -39.00% |
| Return on Investment (5 Year) | -32.11% |